Analytical Services

  • Analytical Services 1
  • Analytical Services 2
  • Analytical Services 3
Product Description

Mabion offers a extensive suite of Analytical Services to ensure safety, efficacy and quality of your biologic product. Our portfolio includes development, optimization and validation of analytical methods, as well as stability studies, GMP release testing and in-depth drug characterization. In addition to routine analytics, we also offer our expertise in biosimilarity and comparability studies. With our cutting-edge equipment we provide you with comprehensive tools for analyzing key physicochemical, structural and biological attributes of your molecules. With a focus on precision and compliance, Mabion’s analytical capabilities can support your product from early development to commercial release.

Read more Show less

Mabion SA

  • Country/Region:
    Poland
  • On CPHI since:
    2023
  • Certificates:
    3
  • Employees:
    250 - 499
Company types
CMO/CDMO
Primary activities
Analytical Services
Biopharmaceutical
Clinical Research
Contract Manufacturer
Contract Research Organisation
End-product distributor (Wholesale)
Intermediates Manufacturer
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Experienced Technicians; International Approvals/Standards; Product Performance; Quality Service; Cell Line Development and Cell Banking services in-house
  • Model
    Service
  • Supplied from
    Poland
  • Measured In
    Euro; US$
More specifications Fewer specifications
Sales Markets
Show more Show less

Mabion SA

  • Country/Region:
    Poland
  • On CPHI since:
    2023
  • Certificates:
    3
  • Employees:
    250 - 499
Company types
CMO/CDMO
Primary activities
Analytical Services
Biopharmaceutical
Clinical Research
Contract Manufacturer
Contract Research Organisation
End-product distributor (Wholesale)
Intermediates Manufacturer
View company profile

More Products from Mabion SA (2)

  • MabionCD20

    Product MabionCD20

    This is our most advanced in-house project. A MabThera/Rituxan (rituximab) biosimilar drug, whose efficacy and safety were clinically confirmed. It is the first such advanced drug developed in Poland. We are currently at the final stage of works aimed at marketing the drug in Europe and the United States.
  • Drug Substance Manufacturing services

    Product Drug Substance Manufacturing services

    Mabion offers advanced Drug Substance Manufacturing services encompassing various types of biologics, antibodies (including multi-specifics and ADC), fusion proteins, enzymes and vaccine antigens. Our state-of-the-art facilities offer 25L – 8000L scale GMP DS batch size for mammalian and insect cell line p...

Mabion SA resources (2)